Pharmatest offers efficacy models for oncology and skeletal diseases, and it is our strategy to constantly develop new models and improve existing models within these indication areas. Within oncology our focus is in orthotopic and metastasis models especially in cancers that develop bone metastases, such as breast, prostate and lung cancer and multiple myeloma. We also have various R&D activities in immuno-oncology, such as establishing disease models with humanized mouse models and immune cell killing assays in vitro. In the field of skeletal disease, our focus is in rare bone diseases, bone safety and versatile bone cell cultures.
Pharmatest is an advisory member in the Academy of Finland funded NanOrganoid consortium that aims at developing nanocellulose-based scaffolds for preclinical organoid models. Pharmatest has also participated in the following EU-projects in previous years: